HCM
DMAA

Heights Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Heights Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.83M Hold
650,000
– – 1.9% 8
2025
Q4 		$6.74M Hold
650,000
– – 2.42% 5
2025
Q3 		$6.68M Hold
650,000
– – 1.9% 10
2025
Q2 		$6.63M Buy
+650,000
New +$6.57M 1.77% 15

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Heights Capital Management's DMAA Position: Q1 2026 in Review

Heights Capital Management held its Drugs Made In America Acquisition Corp (DMAA) position steady in Q1 2026 at 650,000 shares worth $6.83M. The position accounts for 1.9% of the portfolio, ranked #8.

Heights Capital Management first reported a position in DMAA in Q2 2025 and has held it in 4 quarters since. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Heights Capital Management held 650,000 shares of Drugs Made In America Acquisition Corp worth $6.83M as of Q1 2026.
  • Heights Capital Management left its Drugs Made In America Acquisition Corp share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp made up 1.9% of Heights Capital Management's portfolio in Q1 2026, its #8 holding.
  • Heights Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and has held it in 4 quarters since.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.